Melanoma Clinical Trial
Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)
Summary
This is a prospective multicenter, matched case-control study of patients with primary indeterminate lesions or choroidal melanoma who receive treatment with AU-011 and patients who are planned to receive standard of care (SOC) treatment with plaque radiotherapy (plaque) to compare the visual outcomes of AU-011 and plaque radiotherapy.
Full Description
Up to approximately 45 patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the Investigator are planned to be enrolled.
Eligibility Criteria
Have per the investigator's expert clinical judgment, a clinical diagnosis of primary indeterminate lesion or choroidal melanoma based on the clinical history, ophthalmic examination, fundus photography and conventional ocular ultrasound.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 7 Locations for this study
Royal Oak Michigan, 48073, United States
Portland Oregon, 97239, United States
Greenville South Carolina, 29605, United States
Nashville Tennessee, 37203, United States
Bellaire Texas, 77401, United States
Dallas Texas, 75231, United States
Madison Wisconsin, 53705, United States
How clear is this clinincal trial information?